Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Zagami

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
ESMO Open|June 5, 2025
Can selective estrogen receptor-α covalent antagonist (SERCA) be a new treatment for breast cancer?P Zagami, D Trapani
Journal of Neurovirology|June 29, 2000
A cost evaluation of multiple sclerosisM A Battaglia, P Zagami, M M Uccelli
ESMO Open|September 10, 2024
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?P Zagami, J Cortés, L A Carey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2002
The interdisciplinary approach to the treatment of multiple sclerosis patients in Italy: an aspiration or a reality?Uccelli M Messmer, M A Battaglia, P Zagami, et al.
Stroke|December 1, 1995
Carotid diameter, wall thickness, and parietal stress in essential hypertensionM Del Sette, P Zagami, S Angeli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2004
Peer support groups in multiple sclerosis: current effectiveness and future directionsM Messmer Uccelli, L Mancuso Mohr, M A Battaglia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2A Marra, D Generali, P Zagami, et al.
American Journal of Hypertension|May 5, 2001
5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertensionM Ravera, F Viazzi, V Berruti, et al.
ESMO Open|July 19, 2023
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failureG Antonarelli, C Corti, P Tarantino, et al.
ESMO Open|October 16, 2025
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancerG Antonarelli, M Milano, C Andreon, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
ESMO Open|June 5, 2025
Can selective estrogen receptor-α covalent antagonist (SERCA) be a new treatment for breast cancer?P Zagami, D Trapani
Journal of Neurovirology|June 29, 2000
A cost evaluation of multiple sclerosisM A Battaglia, P Zagami, M M Uccelli
ESMO Open|September 10, 2024
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?P Zagami, J Cortés, L A Carey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2002
The interdisciplinary approach to the treatment of multiple sclerosis patients in Italy: an aspiration or a reality?Uccelli M Messmer, M A Battaglia, P Zagami, et al.
Stroke|December 1, 1995
Carotid diameter, wall thickness, and parietal stress in essential hypertensionM Del Sette, P Zagami, S Angeli, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2004
Peer support groups in multiple sclerosis: current effectiveness and future directionsM Messmer Uccelli, L Mancuso Mohr, M A Battaglia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2A Marra, D Generali, P Zagami, et al.
American Journal of Hypertension|May 5, 2001
5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertensionM Ravera, F Viazzi, V Berruti, et al.
ESMO Open|July 19, 2023
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failureG Antonarelli, C Corti, P Tarantino, et al.
ESMO Open|October 16, 2025
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancerG Antonarelli, M Milano, C Andreon, et al.
Pageof 2